Pfizer raises 2026 revenue forecast to $62–64 billion after quarterly results
Pfizer raises 2026 revenue forecast to $62–64 billion after quarterly results
Updated at: November 4, 2026 at 01:20 AM
Pfizer raised its full-year financial outlook on November 3, 2026, after reporting third-quarter results. The drugmaker now forecasts revenue of $62 billion to $64 billion, compared with its previous range of $60.5 billion to $62.5 billion.
The new revenue range lifts the midpoint by $1.5 billion. Pfizer also raised and narrowed its forecast for adjusted diluted earnings per share to $2.95–$3.05, from $2.80–$3.00. Those figures describe the company's expectations for the full year.
Revenue in the completed quarter was approximately $16.6 billion. Pfizer said revenue from its launched and acquired products increased 32 percent operationally and contributed $3.8 billion. That growth measure excludes the effect of changes in foreign exchange rates.
The company also reported different measures of profit per share: 56 cents on a reported diluted basis and 87 cents on an adjusted diluted basis. The adjusted measure is not prepared under US generally accepted accounting principles.
Research remained a major use of capital. Pfizer said it invested $8.3 billion in internal research and development during the first nine months of 2026. It also returned $7.3 billion to shareholders through cash dividends over that period.
The announcement combines quarterly results with annual forecasts. Pfizer attributed the higher outlook to its year-to-date results, confidence in the business and cost-improvement work. The revised ranges remain company guidance, rather than final annual results.
